Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Argus Health
AstraZeneca
Citi
UBS
Colorcon
Queensland Health
Healthtrust

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020164

« Back to Dashboard

NDA 020164 describes LOVENOX (PRESERVATIVE FREE), which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from four suppliers. Additional details are available on the LOVENOX (PRESERVATIVE FREE) profile page.

The generic ingredient in LOVENOX (PRESERVATIVE FREE) is enoxaparin sodium. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.
Summary for 020164
Tradename:LOVENOX (PRESERVATIVE FREE)
Applicant:Sanofi Aventis Us
Ingredient:enoxaparin sodium
Patents:0
Therapeutic Class:Blood Products/Modifiers/ Volume Expanders
Formulation / Manufacturing:see details
Pharmacology for NDA: 020164
Medical Subject Heading (MeSH) Categories for 020164
Suppliers and Packaging for NDA: 020164
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164 NDA sanofi-aventis U.S. LLC 0075-0620 N 0075-0620-41
LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164 NDA sanofi-aventis U.S. LLC 0075-0620 N 0075-0620-40

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength30MG/0.3ML (100MG/ML)
Approval Date:Mar 29, 1993TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength40MG/0.4ML (100MG/ML)
Approval Date:Jan 30, 1998TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength60MG/0.6ML (100MG/ML)
Approval Date:Mar 27, 1998TE:APRLD:Yes

Expired US Patents for NDA 020164

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-001 Mar 29, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-004 Mar 27, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-001 Mar 29, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
US Army
Deloitte
Fuji
AstraZeneca
UBS
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.